CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DBCR::ABL1Fusion AND ABL1 F359CPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,NilotinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 L387FPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinibBradeen et al., 2006
BBRCA2MutationPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparibSwisher et al., 2017
DKITD820YPredictiveSupportsSensitivity/ResponseMelanomaSunitinibAshida et al., 2009
CKITK642EPredictiveSupportsSensitivity/ResponseMucosal MelanomaImatinibLutzky et al., 2008
BMGMTUnderexpressionPredictiveSupportsSensitivity/ResponseOligodendrogliomaTemozolomideLevin et al., 2006
BMGMTUnderexpressionPredictiveSupportsSensitivity/ResponseNeuroendocrine TumorTemozolomideKulke et al., 2009
CEGFRS768IPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibLeventakos et al., 2016
DNRASQ61KPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,TrametinibOhashi et al., 2013
BDNMT3AMutationPredictiveSupportsResistanceCancerAtezolizumab,Nivolumab,PembrolizumabKato et al., 2017
DMAP2K1K57NPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaSelumetinibMarks et al., 2008
BEGFRMutationPredictiveSupportsSensitivity/ResponseLung CancerGefitinibEndoh et al., 2006
Cv::NTRK1FusionPredictiveSupportsSensitivity/ResponseCancerLarotrectinib2016
CLMNA::NTRK1FusionPredictiveSupportsSensitivity/ResponseSarcomaLarotrectinibDoebele et al., 2015
DERBB2L755SPredictiveSupportsResistanceCancerLapatinibKancha et al., 2011
DERBB2L755PPredictiveSupportsResistanceCancerLapatinibKancha et al., 2011
DERBB2T798MPredictiveSupportsResistanceCancerLapatinibKancha et al., 2011
DFLT3D835VPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaCytarabine,SunitinibYee et al., 2004
DFLT3D835VPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaSunitinib,DaunorubicinYee et al., 2004
BFGFR1AmplificationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDovitinibLim et al., 2016
DKITV559DPredictiveSupportsSensitivity/ResponseCancerSunitinib,Imatinib,PD-180970,Tandutinib,DasatinibCarter et al., 2005
CNRASQ61HPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
DKRASG12APredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTeprotumumab,ErlotinibRamalingam et al., 2011
DPIK3CAE545KPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
DPIK3CAE545GPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
BPIK3CAExon 21 MutationPrognosticDoes Not SupportPoor OutcomeColorectal CancerLiao et al., 2012
BPIK3CAMutationPredictiveDoes Not SupportResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
CBCR::ABL1Fusion AND ABL1 F359VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 F359VPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
DBCR::ABL1Fusion AND ABL1 F359VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
BEGFRMutationPredictiveSupportsSensitivity/ResponseLung CancerErlotinibRamalingam et al., 2011
DKRASG12VPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
DBRAFV600E AND KRAS G12DPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
DKRASG12CPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
DKRASG12SPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
CEML4::ALKFusion AND ALK C1156YPredictiveSupportsResistanceLung AdenocarcinomaCrizotinibSaber et al., 2016
BKRASExon 2 MutationPrognosticDoes Not SupportPoor OutcomeRectum CancerHe et al., 2009
DPDGFRAV561DPredictiveDoes Not SupportResistanceCancerSunitinibHeinrich et al., 2008
DPDGFRAD842VPredictiveSupportsResistanceCancerSunitinibHeinrich et al., 2008
DKITV560_L576delPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib AnhydrousGarner et al., 2014
CKITK550_K558delPredictiveSupportsResistanceGastrointestinal Stromal TumorSunitinibHeinrich et al., 2008
DKITV560DPredictiveDoes Not SupportResistanceCancerSunitinibHeinrich et al., 2008
DKITW557_K558delPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib Anhydrous,SunitinibGarner et al., 2014
CKITK558_V559delPredictiveSupportsResistanceGastrointestinal Stromal TumorSunitinibHeinrich et al., 2008
DKITA502_Y503insAYPredictiveDoes Not SupportResistanceCancerSunitinibHeinrich et al., 2008
CBRAFExon 15 MutationPredictiveDoes Not SupportSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib AnhydrousBen-Ami et al., 2016
DKITP551_E554delPMYEPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorPonatinibGarner et al., 2014
CKITL576PPredictiveSupportsResistanceGastrointestinal Stromal TumorSunitinibHeinrich et al., 2008
BKITExon 9 MutationPredictiveSupportsReduced SensitivityGastrointestinal Stromal TumorRegorafenib AnhydrousGeorge et al., 2012
Page 76 of 96
PreviousNext